加齢性黄斑変性症（AMD）の世界市場（～2026年）

• 英文タイトル：Global Wet Age Related Macular Degeneration (AMD) Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY05076 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は加齢性黄斑変性症（AMD）のグローバル市場について調査・分析したレポートです。種類別（湿式加齢性黄斑変性症（湿式AMD）、乾式加齢性黄斑変性症（乾式AMD））市場規模、用途別（75歳以上、60歳以上、40歳以上）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別加齢性黄斑変性症（AMD）の競争状況、市場シェア ・世界の加齢性黄斑変性症（AMD）市場：種類別市場規模 2015年-2020年（湿式加齢性黄斑変性症（湿式AMD）、乾式加齢性黄斑変性症（乾式AMD）） ・世界の加齢性黄斑変性症（AMD）市場：種類別市場規模予測 2021年-2026年（湿式加齢性黄斑変性症（湿式AMD）、乾式加齢性黄斑変性症（乾式AMD）） ・世界の加齢性黄斑変性症（AMD）市場：用途別市場規模 2015年-2020年（75歳以上、60歳以上、40歳以上） ・世界の加齢性黄斑変性症（AMD）市場：用途別市場規模予測 2021年-2026年（75歳以上、60歳以上、40歳以上） ・北米の加齢性黄斑変性症（AMD）市場分析：米国、カナダ ・ヨーロッパの加齢性黄斑変性症（AMD）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの加齢性黄斑変性症（AMD）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の加齢性黄斑変性症（AMD）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの加齢性黄斑変性症（AMD）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis International (Switzerland)、Bayer (Germany)、Acucela (US)、Neurotech Pharmaceuticals (US)、Ophthotech (US)、GlaxoSmithKline (US)、Alimera Sciences (US)、StemCell (Canada)、F. Hoffmann-La Roche (Switzerland)、Regeneron Pharmaceutical (US)、Allergan (Ireland)、Adverum Biotechnologies (US)、Gilead Sciences (US) ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.
Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.

Market Analysis and Insights: Global Wet Age Related Macular Degeneration (AMD) Market
The global Wet Age Related Macular Degeneration (AMD) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Wet Age Related Macular Degeneration (AMD) Scope and Market Size
Wet Age Related Macular Degeneration (AMD) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Wet Age Related Macular Degeneration (AMD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Novartis International (Switzerland)
Bayer (Germany)
Acucela (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
GlaxoSmithKline (US)
Alimera Sciences (US)
StemCell (Canada)
F. Hoffmann-La Roche (Switzerland)
Regeneron Pharmaceutical (US)
Allergan (Ireland)
Adverum Biotechnologies (US)
Gilead Sciences (US)

Market segment by Type, the product can be split into
Wet Age-Related Macular Degeneration (Wet AMD)
Dry Age-Related Macular Degeneration (Dry AMD)
Market segment by Application, split into
Above 75 Years
Above 60 Years
Above 40 Years

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Wet Age Related Macular Degeneration (AMD) Revenue
1.4 Market by Type
1.4.1 Global Wet Age Related Macular Degeneration (AMD) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Wet Age-Related Macular Degeneration (Wet AMD)
1.4.3 Dry Age-Related Macular Degeneration (Dry AMD)
1.5 Market by Application
1.5.1 Global Wet Age Related Macular Degeneration (AMD) Market Share by Application: 2020 VS 2026
1.5.2 Above 75 Years
1.5.3 Above 60 Years
1.5.4 Above 40 Years
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Wet Age Related Macular Degeneration (AMD) Market Perspective (2015-2026)
2.2 Global Wet Age Related Macular Degeneration (AMD) Growth Trends by Regions
2.2.1 Wet Age Related Macular Degeneration (AMD) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Wet Age Related Macular Degeneration (AMD) Historic Market Share by Regions (2015-2020)
2.2.3 Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Wet Age Related Macular Degeneration (AMD) Market Growth Strategy
2.3.6 Primary Interviews with Key Wet Age Related Macular Degeneration (AMD) Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Wet Age Related Macular Degeneration (AMD) Players by Market Size
3.1.1 Global Top Wet Age Related Macular Degeneration (AMD) Players by Revenue (2015-2020)
3.1.2 Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Players (2015-2020)
3.1.3 Global Wet Age Related Macular Degeneration (AMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Wet Age Related Macular Degeneration (AMD) Market Concentration Ratio
3.2.1 Global Wet Age Related Macular Degeneration (AMD) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Wet Age Related Macular Degeneration (AMD) Revenue in 2019
3.3 Wet Age Related Macular Degeneration (AMD) Key Players Head office and Area Served
3.4 Key Players Wet Age Related Macular Degeneration (AMD) Product Solution and Service
3.5 Date of Enter into Wet Age Related Macular Degeneration (AMD) Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Type (2015-2020)
4.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)
5.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Wet Age Related Macular Degeneration (AMD) Market Size (2015-2020)
6.2 Wet Age Related Macular Degeneration (AMD) Key Players in North America (2019-2020)
6.3 North America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
6.4 North America Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)

7 Europe
7.1 Europe Wet Age Related Macular Degeneration (AMD) Market Size (2015-2020)
7.2 Wet Age Related Macular Degeneration (AMD) Key Players in Europe (2019-2020)
7.3 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
7.4 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)

8 China
8.1 China Wet Age Related Macular Degeneration (AMD) Market Size (2015-2020)
8.2 Wet Age Related Macular Degeneration (AMD) Key Players in China (2019-2020)
8.3 China Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
8.4 China Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)

9 Japan
9.1 Japan Wet Age Related Macular Degeneration (AMD) Market Size (2015-2020)
9.2 Wet Age Related Macular Degeneration (AMD) Key Players in Japan (2019-2020)
9.3 Japan Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
9.4 Japan Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size (2015-2020)
10.2 Wet Age Related Macular Degeneration (AMD) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
10.4 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)

11 India
11.1 India Wet Age Related Macular Degeneration (AMD) Market Size (2015-2020)
11.2 Wet Age Related Macular Degeneration (AMD) Key Players in India (2019-2020)
11.3 India Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
11.4 India Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Wet Age Related Macular Degeneration (AMD) Market Size (2015-2020)
12.2 Wet Age Related Macular Degeneration (AMD) Key Players in Central & South America (2019-2020)
12.3 Central & South America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
12.4 Central & South America Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Novartis International (Switzerland)
13.1.1 Novartis International (Switzerland) Company Details
13.1.2 Novartis International (Switzerland) Business Overview
13.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Introduction
13.1.4 Novartis International (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020))
13.1.5 Novartis International (Switzerland) Recent Development
13.2 Bayer (Germany)
13.2.1 Bayer (Germany) Company Details
13.2.2 Bayer (Germany) Business Overview
13.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Introduction
13.2.4 Bayer (Germany) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
13.2.5 Bayer (Germany) Recent Development
13.3 Acucela (US)
13.3.1 Acucela (US) Company Details
13.3.2 Acucela (US) Business Overview
13.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Introduction
13.3.4 Acucela (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
13.3.5 Acucela (US) Recent Development
13.4 Neurotech Pharmaceuticals (US)
13.4.1 Neurotech Pharmaceuticals (US) Company Details
13.4.2 Neurotech Pharmaceuticals (US) Business Overview
13.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Introduction
13.4.4 Neurotech Pharmaceuticals (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
13.4.5 Neurotech Pharmaceuticals (US) Recent Development
13.5 Ophthotech (US)
13.5.1 Ophthotech (US) Company Details
13.5.2 Ophthotech (US) Business Overview
13.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Introduction
13.5.4 Ophthotech (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
13.5.5 Ophthotech (US) Recent Development
13.6 GlaxoSmithKline (US)
13.6.1 GlaxoSmithKline (US) Company Details
13.6.2 GlaxoSmithKline (US) Business Overview
13.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Introduction
13.6.4 GlaxoSmithKline (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
13.6.5 GlaxoSmithKline (US) Recent Development
13.7 Alimera Sciences (US)
13.7.1 Alimera Sciences (US) Company Details
13.7.2 Alimera Sciences (US) Business Overview
13.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Introduction
13.7.4 Alimera Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
13.7.5 Alimera Sciences (US) Recent Development
13.8 StemCell (Canada)
13.8.1 StemCell (Canada) Company Details
13.8.2 StemCell (Canada) Business Overview
13.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Introduction
13.8.4 StemCell (Canada) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
13.8.5 StemCell (Canada) Recent Development
13.9 F. Hoffmann-La Roche (Switzerland)
13.9.1 F. Hoffmann-La Roche (Switzerland) Company Details
13.9.2 F. Hoffmann-La Roche (Switzerland) Business Overview
13.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Introduction
13.9.4 F. Hoffmann-La Roche (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
13.9.5 F. Hoffmann-La Roche (Switzerland) Recent Development
13.10 Regeneron Pharmaceutical (US)
13.10.1 Regeneron Pharmaceutical (US) Company Details
13.10.2 Regeneron Pharmaceutical (US) Business Overview
13.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Introduction
13.10.4 Regeneron Pharmaceutical (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
13.10.5 Regeneron Pharmaceutical (US) Recent Development
13.11 Allergan (Ireland)
10.11.1 Allergan (Ireland) Company Details
10.11.2 Allergan (Ireland) Business Overview
10.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Introduction
10.11.4 Allergan (Ireland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
10.11.5 Allergan (Ireland) Recent Development
13.12 Adverum Biotechnologies (US)
10.12.1 Adverum Biotechnologies (US) Company Details
10.12.2 Adverum Biotechnologies (US) Business Overview
10.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Introduction
10.12.4 Adverum Biotechnologies (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
10.12.5 Adverum Biotechnologies (US) Recent Development
13.13 Gilead Sciences (US)
10.13.1 Gilead Sciences (US) Company Details
10.13.2 Gilead Sciences (US) Business Overview
10.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Introduction
10.13.4 Gilead Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
10.13.5 Gilead Sciences (US) Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Wet Age Related Macular Degeneration (AMD) Key Market Segments
Table 2. Key Players Covered: Ranking by Wet Age Related Macular Degeneration (AMD) Revenue
Table 3. Ranking of Global Top Wet Age Related Macular Degeneration (AMD) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Wet Age Related Macular Degeneration (AMD) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Wet Age-Related Macular Degeneration (Wet AMD)
Table 6. Key Players of Dry Age-Related Macular Degeneration (Dry AMD)
Table 7. Global Wet Age Related Macular Degeneration (AMD) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Wet Age Related Macular Degeneration (AMD) Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Wet Age Related Macular Degeneration (AMD) Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Wet Age Related Macular Degeneration (AMD) Market Share by Regions (2015-2020)
Table 11. Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Wet Age Related Macular Degeneration (AMD) Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Wet Age Related Macular Degeneration (AMD) Market Growth Strategy
Table 17. Main Points Interviewed from Key Wet Age Related Macular Degeneration (AMD) Players
Table 18. Global Wet Age Related Macular Degeneration (AMD) Revenue by Players (2015-2020) (Million US$)
Table 19. Global Wet Age Related Macular Degeneration (AMD) Market Share by Players (2015-2020)
Table 20. Global Top Wet Age Related Macular Degeneration (AMD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Wet Age Related Macular Degeneration (AMD) as of 2019)
Table 21. Global Wet Age Related Macular Degeneration (AMD) by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Wet Age Related Macular Degeneration (AMD) Product Solution and Service
Table 24. Date of Enter into Wet Age Related Macular Degeneration (AMD) Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020) (Million US$)
Table 27. Global Wet Age Related Macular Degeneration (AMD) Market Size Share by Type (2015-2020)
Table 28. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Type (2021-2026)
Table 29. Global Wet Age Related Macular Degeneration (AMD) Market Size Share by Application (2015-2020)
Table 30. Global Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020) (Million US$)
Table 31. Global Wet Age Related Macular Degeneration (AMD) Market Size Share by Application (2021-2026)
Table 32. North America Key Players Wet Age Related Macular Degeneration (AMD) Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Wet Age Related Macular Degeneration (AMD) Market Share (2019-2020)
Table 34. North America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020) (Million US$)
Table 35. North America Wet Age Related Macular Degeneration (AMD) Market Share by Type (2015-2020)
Table 36. North America Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020) (Million US$)
Table 37. North America Wet Age Related Macular Degeneration (AMD) Market Share by Application (2015-2020)
Table 38. Europe Key Players Wet Age Related Macular Degeneration (AMD) Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Wet Age Related Macular Degeneration (AMD) Market Share (2019-2020)
Table 40. Europe Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Wet Age Related Macular Degeneration (AMD) Market Share by Type (2015-2020)
Table 42. Europe Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Wet Age Related Macular Degeneration (AMD) Market Share by Application (2015-2020)
Table 44. China Key Players Wet Age Related Macular Degeneration (AMD) Revenue (2019-2020) (Million US$)
Table 45. China Key Players Wet Age Related Macular Degeneration (AMD) Market Share (2019-2020)
Table 46. China Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020) (Million US$)
Table 47. China Wet Age Related Macular Degeneration (AMD) Market Share by Type (2015-2020)
Table 48. China Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020) (Million US$)
Table 49. China Wet Age Related Macular Degeneration (AMD) Market Share by Application (2015-2020)
Table 50. Japan Key Players Wet Age Related Macular Degeneration (AMD) Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Wet Age Related Macular Degeneration (AMD) Market Share (2019-2020)
Table 52. Japan Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Wet Age Related Macular Degeneration (AMD) Market Share by Type (2015-2020)
Table 54. Japan Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Wet Age Related Macular Degeneration (AMD) Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Wet Age Related Macular Degeneration (AMD) Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Wet Age Related Macular Degeneration (AMD) Market Share (2019-2020)
Table 58. Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Share by Type (2015-2020)
Table 60. Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Share by Application (2015-2020)
Table 62. India Key Players Wet Age Related Macular Degeneration (AMD) Revenue (2019-2020) (Million US$)
Table 63. India Key Players Wet Age Related Macular Degeneration (AMD) Market Share (2019-2020)
Table 64. India Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020) (Million US$)
Table 65. India Wet Age Related Macular Degeneration (AMD) Market Share by Type (2015-2020)
Table 66. India Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020) (Million US$)
Table 67. India Wet Age Related Macular Degeneration (AMD) Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Wet Age Related Macular Degeneration (AMD) Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Wet Age Related Macular Degeneration (AMD) Market Share (2019-2020)
Table 70. Central & South America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Wet Age Related Macular Degeneration (AMD) Market Share by Type (2015-2020)
Table 72. Central & South America Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Wet Age Related Macular Degeneration (AMD) Market Share by Application (2015-2020)
Table 74. Novartis International (Switzerland) Company Details
Table 75. Novartis International (Switzerland) Business Overview
Table 76. Novartis International (Switzerland) Product
Table 77. Novartis International (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 78. Novartis International (Switzerland) Recent Development
Table 79. Bayer (Germany) Company Details
Table 80. Bayer (Germany) Business Overview
Table 81. Bayer (Germany) Product
Table 82. Bayer (Germany) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 83. Bayer (Germany) Recent Development
Table 84. Acucela (US) Company Details
Table 85. Acucela (US) Business Overview
Table 86. Acucela (US) Product
Table 87. Acucela (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 88. Acucela (US) Recent Development
Table 89. Neurotech Pharmaceuticals (US) Company Details
Table 90. Neurotech Pharmaceuticals (US) Business Overview
Table 91. Neurotech Pharmaceuticals (US) Product
Table 92. Neurotech Pharmaceuticals (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 93. Neurotech Pharmaceuticals (US) Recent Development
Table 94. Ophthotech (US) Company Details
Table 95. Ophthotech (US) Business Overview
Table 96. Ophthotech (US) Product
Table 97. Ophthotech (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 98. Ophthotech (US) Recent Development
Table 99. GlaxoSmithKline (US) Company Details
Table 100. GlaxoSmithKline (US) Business Overview
Table 101. GlaxoSmithKline (US) Product
Table 102. GlaxoSmithKline (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 103. GlaxoSmithKline (US) Recent Development
Table 104. Alimera Sciences (US) Company Details
Table 105. Alimera Sciences (US) Business Overview
Table 106. Alimera Sciences (US) Product
Table 107. Alimera Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 108. Alimera Sciences (US) Recent Development
Table 109. StemCell (Canada) Business Overview
Table 110. StemCell (Canada) Product
Table 111. StemCell (Canada) Company Details
Table 112. StemCell (Canada) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 113. StemCell (Canada) Recent Development
Table 114. F. Hoffmann-La Roche (Switzerland) Company Details
Table 115. F. Hoffmann-La Roche (Switzerland) Business Overview
Table 116. F. Hoffmann-La Roche (Switzerland) Product
Table 117. F. Hoffmann-La Roche (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 118. F. Hoffmann-La Roche (Switzerland) Recent Development
Table 119. Regeneron Pharmaceutical (US) Company Details
Table 120. Regeneron Pharmaceutical (US) Business Overview
Table 121. Regeneron Pharmaceutical (US) Product
Table 122. Regeneron Pharmaceutical (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 123. Regeneron Pharmaceutical (US) Recent Development
Table 124. Allergan (Ireland) Company Details
Table 125. Allergan (Ireland) Business Overview
Table 126. Allergan (Ireland) Product
Table 127. Allergan (Ireland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 128. Allergan (Ireland) Recent Development
Table 129. Adverum Biotechnologies (US) Company Details
Table 130. Adverum Biotechnologies (US) Business Overview
Table 131. Adverum Biotechnologies (US) Product
Table 132. Adverum Biotechnologies (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 133. Adverum Biotechnologies (US) Recent Development
Table 134. Gilead Sciences (US) Company Details
Table 135. Gilead Sciences (US) Business Overview
Table 136. Gilead Sciences (US) Product
Table 137. Gilead Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020) (Million US$)
Table 138. Gilead Sciences (US) Recent Development
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Wet Age Related Macular Degeneration (AMD) Market Share by Type: 2020 VS 2026
Figure 2. Wet Age-Related Macular Degeneration (Wet AMD) Features
Figure 3. Dry Age-Related Macular Degeneration (Dry AMD) Features
Figure 4. Global Wet Age Related Macular Degeneration (AMD) Market Share by Application: 2020 VS 2026
Figure 5. Above 75 Years Case Studies
Figure 6. Above 60 Years Case Studies
Figure 7. Above 40 Years Case Studies
Figure 8. Wet Age Related Macular Degeneration (AMD) Report Years Considered
Figure 9. Global Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Wet Age Related Macular Degeneration (AMD) Market Share by Regions: 2020 VS 2026
Figure 11. Global Wet Age Related Macular Degeneration (AMD) Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Wet Age Related Macular Degeneration (AMD) Market Share by Players in 2019
Figure 14. Global Top Wet Age Related Macular Degeneration (AMD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Wet Age Related Macular Degeneration (AMD) as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Wet Age Related Macular Degeneration (AMD) Revenue in 2019
Figure 16. North America Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed

---